Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Open access
van den Berg, Joost H, Heemskerk, Bianca, van Rooij, Nienke, Gomez-Eerland, Raquel, Michels, Samira, van Zon, Maaike, de Boer, Renate, Bakker, Noor A M, Jorritsma-Smit, Annelies, van Buuren, Marit M, Kvistborg, Pia, Spits, Hergen, Schotte, Remko, Mallo, Henk, Karger, Matthias, van der Hage, Joris A, Wouters, Michel W J M, Pronk, Loes M, Geukes Foppen, Marnix H, Blank, Christian U, Beijnen, Jos H, Nuijen, Bastiaan, Schumacher, Ton N, Haanen, John B A G · 2020 · Journal for ImmunoTherapy of Cancer

Abstract

Treatment of metastatic melanoma with autologous tumor infiltrating lymphocytes (TILs) is currently applied in several centers. Robust and remarkably consistent overall response rates, of around 50% of treated patients, have been observed across hospitals, including a substantial fraction of durable, complete responses. Purpose: Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized phase III trial. Experimental: Ten patients were treated with TIL therapy. Infusion products and peripheral blood samples were phenotypically characterized and neoantigen reactivity was assessed. Here, we present long-term clinical outcome and translational data on neoantigen reactivity of the T cell products. Results: Five out of 10 patients, who were all anti-PD-1 naïve at time of treatment, showed an objective clinical response, including two patients with a complete response that are both ongoing for more than 7 years. Immune monitoring demonstrated that neoantigen-specific T cells were detectable in TIL infusion products from three out of three patients analyzed. For six out of the nine neoantigen-specific T cell responses detected in these TIL products, T cell response magnitude increased significantly in the peripheral blood compartment after therapy, and neoantigen-specific T cells were detectable for up to 3 years after TIL infusion. Conclusion: The clinical results from this study confirm the robustness of TIL therapy in metastatic melanoma and the potential role of neoantigen-specific T cell reactivity. In addition, the data from this study supported the rationale to initiate an ongoing multicenter phase III TIL trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-000848

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 194

Metadata

Authors
van den Berg, J. H., Heemskerk, B., van Rooij, N., Gomez-Eerland, R., Michels, S., van Zon, M., de Boer, R., Bakker, N. A. M., Jorritsma-Smit, A., van Buuren, M. M., Kvistborg, P., Spits, H., Schotte, R., Mallo, H., Karger, M., van der Hage, J. A., Wouters, M. W. J. M., Pronk, L. M., Geukes Foppen, M. H., Blank, C. U., Beijnen, J. H., Nuijen, B., Schumacher, T. N., & Haanen, J. B. A. G.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-08
Volume
8
Issue
2
Pages
e000848
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3047394062
Cited by
194
References
9
FWCI
7.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. https://app.cochat.ai/papers/10.1136/jitc-2020-000848
The paper
van den Berg, J. H., Heemskerk, B., van Rooij, N., Gomez-Eerland, R., Michels, S., van Zon, M., de Boer, R., Bakker, N. A. M., Jorritsma-Smit, A., van Buuren, M. M., Kvistborg, P., Spits, H., Schotte, R., Mallo, H., Karger, M., van der Hage, J. A., Wouters, M. W. J. M., Pronk, L. M., Geukes Foppen, M. H., . . . Haanen, J. B. A. G. (2020). Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-000848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.